Congress Proceedings - First International Workshop. Neurological Problems and Liver Transplantation: Current perspective on immunosuppression used in liver transplantation with emphasis on neurotoxicity

A. B. Jain, R. Kashyap, J. J. Fung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since the first successful liver transplant in 1968 by Starzl, survival outcomes have dramatically improved with a resultant increase in the number of transplants performed each year. While there have been improvements in technical and medical approaches to the care of liver transplant patients, probably the single greatest improvement has been in the area of immunosuppressive management. The overall patient survival is currently over 80 at one year and over 60 at nine years. The actuarial nine-year survival in children (aged between 3 and 18 years) is approximately 90. However these improvements have not come about without an associated morbidity. One of the major perioperative complications is the development of neurotoxicity - ranging from mild presentation of tremor and cognitive disorders to major complications of seizure, dysarthria, and cerebropontine myelinolysis. The etiologies of these neurologic complications are multifactorial. The mainstay immunosuppressive agents, cyclosporin and tacrolimus, ave themselves associated with neurotoxicity, and this presentation may be aggravated by post-operative liver dysfunction, renal impairment, metabolic and electrolyte disturbances. Both drugs are inherently nephrotoxic, diabetogenic and hypertensive. Allograft loss from acute and chronic rejection is rare. The majority of late graft losses and deaths are related to: recurrence of disease; non-compliance; the development of de novo malignancies and age-related concurrent medical conditions.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalGastroenterology International
Volume12
Issue number3
StatePublished - Dec 1 1999

Fingerprint

Liver Transplantation
Immunosuppression
Transplants
Education
Immunosuppressive Agents
Survival
Dysarthria
Liver
Tacrolimus
Tremor
Nervous System
Electrolytes
Cyclosporine
Birds
Allografts
Liver Diseases
Seizures
Morbidity
Kidney
Recurrence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{a137b64ba5e449d4bb3fcbddb3a7b863,
title = "Congress Proceedings - First International Workshop. Neurological Problems and Liver Transplantation: Current perspective on immunosuppression used in liver transplantation with emphasis on neurotoxicity",
abstract = "Since the first successful liver transplant in 1968 by Starzl, survival outcomes have dramatically improved with a resultant increase in the number of transplants performed each year. While there have been improvements in technical and medical approaches to the care of liver transplant patients, probably the single greatest improvement has been in the area of immunosuppressive management. The overall patient survival is currently over 80 at one year and over 60 at nine years. The actuarial nine-year survival in children (aged between 3 and 18 years) is approximately 90. However these improvements have not come about without an associated morbidity. One of the major perioperative complications is the development of neurotoxicity - ranging from mild presentation of tremor and cognitive disorders to major complications of seizure, dysarthria, and cerebropontine myelinolysis. The etiologies of these neurologic complications are multifactorial. The mainstay immunosuppressive agents, cyclosporin and tacrolimus, ave themselves associated with neurotoxicity, and this presentation may be aggravated by post-operative liver dysfunction, renal impairment, metabolic and electrolyte disturbances. Both drugs are inherently nephrotoxic, diabetogenic and hypertensive. Allograft loss from acute and chronic rejection is rare. The majority of late graft losses and deaths are related to: recurrence of disease; non-compliance; the development of de novo malignancies and age-related concurrent medical conditions.",
author = "Jain, {A. B.} and R. Kashyap and Fung, {J. J.}",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "12",
pages = "115--122",
journal = "Gastroenterology International",
issn = "0950-5911",
publisher = "International Universities Press Inc.",
number = "3",

}

TY - JOUR

T1 - Congress Proceedings - First International Workshop. Neurological Problems and Liver Transplantation

T2 - Current perspective on immunosuppression used in liver transplantation with emphasis on neurotoxicity

AU - Jain, A. B.

AU - Kashyap, R.

AU - Fung, J. J.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Since the first successful liver transplant in 1968 by Starzl, survival outcomes have dramatically improved with a resultant increase in the number of transplants performed each year. While there have been improvements in technical and medical approaches to the care of liver transplant patients, probably the single greatest improvement has been in the area of immunosuppressive management. The overall patient survival is currently over 80 at one year and over 60 at nine years. The actuarial nine-year survival in children (aged between 3 and 18 years) is approximately 90. However these improvements have not come about without an associated morbidity. One of the major perioperative complications is the development of neurotoxicity - ranging from mild presentation of tremor and cognitive disorders to major complications of seizure, dysarthria, and cerebropontine myelinolysis. The etiologies of these neurologic complications are multifactorial. The mainstay immunosuppressive agents, cyclosporin and tacrolimus, ave themselves associated with neurotoxicity, and this presentation may be aggravated by post-operative liver dysfunction, renal impairment, metabolic and electrolyte disturbances. Both drugs are inherently nephrotoxic, diabetogenic and hypertensive. Allograft loss from acute and chronic rejection is rare. The majority of late graft losses and deaths are related to: recurrence of disease; non-compliance; the development of de novo malignancies and age-related concurrent medical conditions.

AB - Since the first successful liver transplant in 1968 by Starzl, survival outcomes have dramatically improved with a resultant increase in the number of transplants performed each year. While there have been improvements in technical and medical approaches to the care of liver transplant patients, probably the single greatest improvement has been in the area of immunosuppressive management. The overall patient survival is currently over 80 at one year and over 60 at nine years. The actuarial nine-year survival in children (aged between 3 and 18 years) is approximately 90. However these improvements have not come about without an associated morbidity. One of the major perioperative complications is the development of neurotoxicity - ranging from mild presentation of tremor and cognitive disorders to major complications of seizure, dysarthria, and cerebropontine myelinolysis. The etiologies of these neurologic complications are multifactorial. The mainstay immunosuppressive agents, cyclosporin and tacrolimus, ave themselves associated with neurotoxicity, and this presentation may be aggravated by post-operative liver dysfunction, renal impairment, metabolic and electrolyte disturbances. Both drugs are inherently nephrotoxic, diabetogenic and hypertensive. Allograft loss from acute and chronic rejection is rare. The majority of late graft losses and deaths are related to: recurrence of disease; non-compliance; the development of de novo malignancies and age-related concurrent medical conditions.

UR - http://www.scopus.com/inward/record.url?scp=0033402146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033402146&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033402146

VL - 12

SP - 115

EP - 122

JO - Gastroenterology International

JF - Gastroenterology International

SN - 0950-5911

IS - 3

ER -